teries, femoral arteries, and abdominal aorta. The cases were then subdivided into three subgroups on the basis of the positivity to the three subpopulations of aPL. Results demonstrate that there is no correlation between aPL and atherosclerosis. The different positivity to aPL does not modify this conclusion.
Summary: The purpose of this study was to check whether antiphospholipid antibodies (aPL) could be an independent risk factor for atherosclerosis. Eighty-five subjects were studied: 45 with primitive antiphospholipid antibody syndrome and 40 controls affected by deep vein thrombosis secondary to known causes. The two groups were homogeneous for age, sex, and risk factors for atherosclerosis. All the subjects submitted to echo-color doppler of the carotid ar-Antiphospholipid antibodies (aPL) constitute a heterogeneous group of antibodies that react against antigenic epitopes of the complex phospholipid-proteins (1, 2) and include the anticardiolipin antibody and lupus anticoagulant (LA) (3) (4) (5) .
LA is a subpopulation aPL that determines a prolonged coagulation time in vitro (5) . It seems that LA interferes with the activation of prothrombin in vitro; it is responsible for the inhibition of prothrombin complex (Xa and Va factors, Ca2+, and phospholipids) because of the link to phospholipids. The presence of LA in subjects affected by systemic lupus erythematosus (SLE) is in the 6% to 16% range (9) (10) (11) , and these patients are a particular clinical subgroup because they present a high risk of either arterial or venous thrombosis. There are also aPL with different specificity, directed against plasmatic phospholipid joined to proteins, such as 32-glycopro-tein (,B2-GP1) and prothrombin (12) (13) (14) . The antibody against oxidized-LDL can also be considered as part of the aPL family; the LDL oxidation is responsible for a larger expression of antigenic neoepitopes of apolipoprotein B that favor the production of autoantibodies (15) .
The positivity to these antibodies is associated, in some patients, with an increased risk of recurrent arterial or venous thrombosis, recurrent miscarriages, and thrombocytopenia (16, 17) .This clinical and laboratory event is known as the antiphospholipid antibody syndrome (4, (18) (19) (20) , which can be primary (21, 22) or secondary (23) . The primary form is characterized by the features already explained without the presence of any other pathologic conditions (21, 22) . The secondary form is either associated with SLE (18, 20) or secondary to autoimmune pathologic states (3, 8) , infectious diseases (3, 8, 24) , cancer (3), or drugs (25, 26 ).
The autoimmune system seems to carry out an important role in the progression of atherosclerosis (ATS) (27) . Some authors have described autoantigens as producing an inflammatory reaction and an autoimmune process influencing ATS progression (28) ; aPL can also be considered as belonging to this group (29, 30) .
Other authors maintain that in subjects affected by SLE, the greater precocity of ATS development is also to be referred to aPL positivity (31) (32) (33) . On the basis of these observations, we tried to verify whether aPL are an independent risk factor for atherosclerosis.
SUBJECTS AND METHODS

Subjects
We examined 85 subjects: 45 were affected by idiopathic antiphospholipid antibody syndrome (APS), diagnosed 7 years previously. When we began the study, 38 patients presented deep vein thrombosis (DVT), in five cases associated with pulmonary embolism and in seven with thrombocytopenia. The control group was made up of 40 subjects with thrombosis secondary to trauma, surgery, prolonged immobilization in bed, solid cancer (lung or bladder), and fractures.
We excluded subjects with pathologic conditions associated with atherosclerosis such as acute myocardial infarction, angina pectoris, transient ischemic attacks, stroke, murmur, carotid endoarteriectomy, obliterating arteriopathy of the leg, and aortic aneurysm. Also excluded were patients with autoimmune or immunoproliferative pathology, thyroid pathology, or subjects using steroid or contraceptive drugs. All patients underwent a clinical history, physical examination, thoracic radiograph, electrocardiography, and routine blood tests ( Table 1) .
The cases were reassessed through clinical and laboratory criteria to confirm the diagnosis of antiphospholipid antibody syndrome. The clinical criteria were deep venous thrombosis or thrombocytopenia. The laboratory criteria were demonstrated via the measure of the three classes of antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-52 glycoprotein) (1) , carried out on two blood samples taken at 2-month intervals.
Measuring Antiphospholipid Antibodies
Lupus anticoagulant To check for LA, hemocoagulative tests measuring coagulation time in vitro, such as A-PTT, were used, making use of specific reacting agents containing a variety of phospholipids. The tests used were:
PTT-LA: Measures A-PTT with the use of TCA, which is a reactive agent with cephalin plus an activator (silica) (34) . The test to check the blood sample will be added to a solution of monosodic citrate 0.109 M with a 9:1 proportion and then in a plastic or glass tube with silicone. The end sample is then spin dried at 2.5 g for 15 minutes with elimination of thrombosis until a 3 maximum value rest of 10/mm3.
The PTT-LA is considered positive when the coagulation time of tested plasma is prolonged and the time calculated in seconds is greater than the medium standard value of 37.5 seconds. This test uses phospholipids in hexagonal phase (123, 124). BMI, body mass index. The tested plasma in which the presence of LA is suspected is incubated at 37.5°C with (tube 2) and without (tube 1) the reactive agent, that is phosphatidilethanolamine (HPE) in hexagonal phase, which is recognized by the lupus type antibody. Then we measured the A-PTT in two vials, using the reactive TCA. From the difference between the coagulation time of the two samples, it is possible to see LA positivity (34) . If the TI-T2 difference is less than 8 seconds, the test is negative; if the TI-T2 difference is greater than 8 seconds, the test is positive.
LA1 and LA2 test (or Russel's adder test): This test determines coagulation time with particularly reactive agents, LA1 and LA2, which contain adder poison (RW), phospholipid, calcium, heparin, and color (<0.001%) that is green in LA1 and red in LA2.
RVV, calcium, and phospholipids in the reactive agents directly activate factors V and X of common reaction of intrinsic and extrinsic view of coagulation. If there is LA in the tested plasma, the coagulation time will be prolonged. The LA2 test is carried out as a confirmation test, in case LA1 is negative. The normality value of the two tests are LA1 less than 45 seconds and LA2 less than 38 seconds. LA positivity is evaluated on the basis of the ratio LA1/LA2 (R): when R is greater than 2, LA positivity is high
PNP-test (Staclot PNP). This test searches for LA with the neutralization of platelets lisation (34, 38) . The plasma with suspected LA is incubated at 37°C with (tube 2) and without (tube 1) platelet lisation; then a reactive agent is added with sensibility to LA (TCA) and A-PTT is measured. If LA were present in tube 2, this would be neutralized by the platelets and coagulation time is then short. From the difference between the coagulation time measured in tube 1 (T1) and in tube 2 (T2), LA positivity can be detected. If the T1-T2 difference is greater than 8 seconds, the test is positive; if the T1-T2 difference is less than 8 seconds, the test is negative.
Anticardiolipin antibody
The search for aCL was carried out with an immunoenzymatic semiquantitative technique (ELISA). The test plasma is incubated in a plastic .0 glass covered with phospholipids; this allows the fixation of antibodies. The fixed antibodies are recognized with an immunojoint (anti IgG and/or IgM and/or IgA, joined to peroxidasis), which is fixed on free antigenic. The presence and the concentration of aCL are indirectly evaluated. In fact the addition of immunojoint is responsible for the activation of the peroxidase added to the test sample, which is responsible for its action in the presence of hydrogen peroxide or ortophenildiamine. The intensity of the color derived from the peroxidation of this substrate, before the reaction is blocked with a strong acid, represents the aCL concentration in the plasma (70).
Anti-,2-glycoprotein 1 antibody For the qualification and quantification of anti-,B2glycoprotein 1, an ELISA test on a sample of serum (34, 38) (Gull Autoimmune ELISA kit) is used, in accordance with indications in the literature. The test is carried out following a protocol present in the kit. The test is considered positive if the antibody titer is greater than 15 mU/mL, it is negative if less than 10 U/mL.
In all these tests for LA, aCL and anti-,B2-glycoprotein 1 trypization, we observed the following rules for the preparation and conservation of the plasma to be tested: * The blood (9 mL), taken from a patient on an empty stomach, was put in a plastic glass with 0.109 M of sodium citrate (1 mL). * This sample was spin dried for 15 minutes at 2500g; in this way the residual platelets may be fewer than 10/mm3. To search for LA, the plasma was spin dried twice. * The obtained plasma can be preserved at 20°C for 8 (aCL and anti-f32GP1) and 4 (LA) hours or for 1 month at -200C.
Echo-Color-Doppler of Carotid Arteries, Leg Arteries, and Abdominal Aorta All the patients underwent echo-color-doppler evaluation of the carotid axis, leg arteries, and abdominal aorta. The test was made with an ATL Apogee 800 plus (USA) instrument and an 8.5-MHz probe for B-mode echography and 6-MHz probe for pulsed doppler.
For the carotid study, the patient lay on the couch with his/her neck rotated 45 degrees. perior), with an incidence angle of 60 degrees. The same method was used for the study of the leg arteries. The patient lay on the couch and the ultrasound technician was sitting by his/her side.
Through a lonaitudinal and a transverse scan, the test studied the femoral common artery, the bifurcation, and the superficial or deep femoral artery. All the arteries were subdivided into three segments (inferior, medium, and superior). For the abdominal aorta, the test was carried out with the same instrument but with a 3.5-MHz probe for the echogram and with a 6-MHz probe for the pulsed doppler. Both a longitudinal and a transverse scan were always carried out.
The abdominal aorta was examined below the celiac tripod origin as far as the iliac arteries. An ultrasound technician carried out the tests, which were all videotaped and reassessed by another ultrasound technician for validation. Discrepant results were further evaluated blindly by a senior expert.
An atherosclerotic plaque was defined as such when the intimal thickness was greater than 2 mm. The plaques were classified as heterogeneous (type I) and homogeneous (type II). The plaques could also be hypo-isoechogenic and the surface was classified as irregular, regular, or ulcerated. There were five subgroups of stenosis grade: low (1%-30%), moderate (31%-50%), serious (51%-69%), severe (70%-99%), and total occlusion (100%), in accordance with the NASCET study. Fluximetric and colorimetric analyses were also carried out.
Statistical Analysis
Chi-square test and Odd's ratio were used.
RESULTS
We studied 85 patients: 45 with APS (M = 15; F = 30; age 47.7 ± 13) and 40 with secondary deep venous thrombosis (M = 15; F = 25; age 47.2 ± 16).
The atherosclerosis risk factors, homogeneous for the two examined groups, are summarized in Table 2 . Even if the subjects with APS show a higher incidence of hypertension (33.5% versus 25%) and diabetes mellitus (17.8% versus 12.5%) and the controls a prevalence of hypercholesterolemia (25% versus 17.8%), these differences were not significant ( Table 3 ).
The prevalence of atherosclerosis in the three explored districts is homogeneous. In the carotid axis, we detected a prevalence of ATS comparable with that of controls (35.6% of cases and 35% of controls). Similar results were found for the femoral arteries and the abdominal aorta: 26.7% of cases versus 20% for femoral arteries, 20% versus 17.5% for the aorta (Table 4 ). The (17.5) extension of ATS expressed in plaque number in every subject (minimum 1, maximum 5) was homogeneous in the two populations. Of 114 plaques of the three explored districts, 60 (52.6%) of the total were found in the cases, 54 (47.3%) in the controls (Table 5) . Table 6 shows the distribution of ATS in the three districts of the APS patients subdivided according to the different positivity to antiphospholipid antibodies. In the subjects with one an-tibody (aCL or LA) (N = 25) the atherosclerosis prevalence was 52%; while in the subjects with two (N = 7) or three (N = 13) antibodies, the prevalence was 57.1% and 69.2%. Table 7 shows the results of the prevalence of the carotid ATS. This was higher for the patients with the three antibodies, but not significant.
The subject with one or two antibodies presented a percentage of ATS of 36% and 28.6%, respectively, the subjects with three antibodies of 38.5%. Only one positive antibody: 13 (52) CL or LA (N = 25) Two positive antibodies: 4 (57.1) 12 GP1 + aCL or LA (N = 7) Three positive antibodies: 9 (69.2) aCL + LA + 2 GP1 (N = 13) Only one positive antibody: 9 (36.0) aCL or LA (N = 25) Two positive antibodies: 2 (28.6) anti-P2 GP1 + aCL or LA (N = 7)
Three positive antibodies: 5 (38.5) aCL + LA + anti-P2 GP1 (N = 13) DISCUSSION APS is characterized by recurrent thrombosis, recurrent miscarriages, variable neurologic patterns, and thrombocytopenia (2, 34) . Some articles have shown a correlation between APA antibodies and atherosclerosis in patients with SLE particularly for coronary ATS (35) and/or carotid ATS (36) . This correlation is responsible for a greater mortality from myocardial and cerebral infarction (31, 37, 38) . Besides the traditional risk factors for atherosclerosis such as hypercholesterolemia (39) , hypertension (40) , diabetes mellitus (41) , smoking (42) , it seems that the immune system may have a role in the progression of atherosclerosis (27) . Various authors have de-scribed autoantigens capable of causing an immune response via a secondary inflammation, which can positively influence the atherosclerotic process (28) . Among the immune factors that can be involved in this reaction, we can also find the antiphospholipid antibodies (28, 30) . In vivo studies in patients affected by SLE (43) or in vitro studies (44, 45) , the subgroup of aPL more responsible for ATS seems to be aCL and anti-,B2GP1. A significant number of patients with SLE have positive results to aCL and anti-,B2GP1; these two antibodies are capable of activating the endothelial cell favoring the adhesion of monocytes (46) . This is one of the first steps of the inflammatory process typical of atherosclerosis. Our study eval-Prevalence of atherosclerosis in the three studied districts in APS lilhiatrfl rnnrfre"nr vonttrG"rfv t0% rnoeMiv;s+^+rhtlft;^S-Anjb 'aJJuL.Lu Lii eL.LJ LuIiuuiu L=rJzyLViLr ELo anupagiiIU:pLIUfILiU aFriouuUies ]50%-40% -30%-. ;@ 20%-g uated the correlation between APS and ATS, and verified whether the antiphospholipid antibody syndrome can be an independent risk factor for ATS.
Our results contrast with those in previous observations: in fact, the subjects with APS did not present a arade of ATS higher than controls. We can then consider the following aspects: first, literature reports correlate the ATS risk with secondary APS, patients with antiphospholipid positivity in SLE subjects; second, SLE patients with aPL positivity (in accordance with Urowitz and Gladman) (47) are located in a complex atherogenic situation.
In SLE patients, an important variation of the lipid pattern can be found: increased VLDL, LDL, Lp(a), and decreased HDL (48, 49) . Other risk factors that we find are increased homocystinemia (50) , the existence of a hypercoagulable state, an increased fibrinogen (51) , and PAI (52) . Of these risk factors, the most important is dyslipidemia, provoked by the steroid therapy. This therapy particularly increases LDL and Lp(a) (53) . Lp(a) is responsible for the oxidation of LDL with the consequent expression of neoantigens with the immune response and production of antibodies antioxidized LDL. This result is discussed as the importance of oxidized LDL and atherosclerosis (54) .
In the literature, the role of aPL for atherosclerosis is studied as the correlation with the cross reactivity and anti-LDLox antibodies (55, 56) . All the studies in vivo are carried out in subjects with SLE, and for this reason we wondered whether anti-LDLox could be an epiphenomenon of the atherosclerotic process induced and accelerated from the increased LDLox of subjects with SLE. In this way, aCL did not have the atherogenic role. From this observation, the results of our study can be important (we did not dose the level of anti-LDLox because they do not define APS). So even if in previous in vivo studies the atherogenic role of aPL was evaluated from their cross-reactivity with LDLox, in our study we did not consider this fact.
It is important to underline the fact that, in previous works, the relationship between aPL and atherogenic risk was not studied in correlation with the morphology of plaques but in function of the prevalence of clinical manifestation associated with it, such as IMA and stroke (57) (58) (59) (60) . Our study with echo-color doppler pointed to an evaluation of the grade of atherosclerosis, certainly quantifiable (61) with a morphologic study, very important for the prognosis of cerebrovascular events (62) . In fact, the study of carotid ATS can be a useful modality to define in a simple and noninvasive way the presence of ATS and its progression of all the arterial districts (63) and particularly of coronary arteries (64) . The results obtained for APS subjects demonstrate that aPL is not an independent risk factor for ATS. However, a prospective study will be useful for the evaluation of the progression of atherosclerosis in these patients.
